BioSig Technologies today announced that it has chosen Plexus as its manufacturing partner.
Neenah, Wisconsin-based Plexus will bring to market the Pure EP system, which is the company’s signal processing technology for arrhythmia care, and will develop a new product pipeline for BioSig’s NeuroClear Technologies.
“We are fundamentally proud to partner with Plexus on our mission to advance therapies through technological innovation. Their engineering and manufacturing capabilities and outstanding expertise in building complex medical devices make Plexus a foundational cornerstone to support BioSig’s growth objectives now and well into the future,” BioSig CEO Kenneth Londoner said in a news release. “The recent release of our clinical data has increased physician interest in our technology. We believe that the post-pandemic recovery in elective procedures will further drive our installation footprint, and we are confident that Plexus’ first-class operational infrastructure will ensure a quality supply of the PURE EP™ systems to meet growing market needs.”
Pure EP is a non-invasive Class II device that drives procedural efficiency and efficacy in cardiac electrophysiology.
“We are proud to partner with BioSig in helping to bring their Pure EP System to market. The Pure EP System is an innovative, breakthrough device that will greatly improve the healthcare opportunities for physicians and patients alike. Through this partnership, we look forward to furthering our vision of helping create the products that build a better world,” said Michael Tendick, VP of healthcare and life sciences at Plexus.
The company said it will focus on commercially launching the Pure EP System in the Northeast, Texas and Florida.